Total Intravenous Versus Inhalational Anesthesia- A Geriatric Anesthesia Study
Oregon Health and Science University · NCT06036095
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 70–110 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Phase 4
- Target enrollment
- 260
- US sites recruiting
- 1
- Study start
- August 14, 2023
- Record last updated
- April 8, 2024
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
Traditionally, general anesthesia is maintained with inhalational anesthesia (GAS), but there is a gap in knowledge regarding whether intravenous anesthesia (IV) can prevent deleterious postoperative outcomes in the geriatric surgical population. The goal of this clinical trial is to determine whether intravenous anesthesia (IV) leads to a decreased incidence of postoperative delirium (POD), postoperative cognitive dysfunction (POCD), and functional decline, and improved patient-reported outcomes (PROs) in older adults undergoing non-cardiac surgery when compared to the standard inhalational anesthesia (GAS). This single-center, 1:1 randomized, double-blind (patient \& outcome assessor) clinical trial will compare inhalational vs. intravenous anesthesia on POD, POCD, functional status, patient-reported outcomes (PROs), and blood-based biomarkers in older patients undergoing elective, inpatient, non-cardiac surgery. Upon enrollment, 260 women and men ≥ 70 years undergoing elective noncardiac surgery under general anesthesia will be randomized to 2 groups: TIVA or GAS.
Being studied: Sevoflurane; Propofol
Conditions: Neurocognitive Disorders; Anesthesia; Post-operative Delirium; Post-operative Cognitive Dysfunction
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion criteria
- Men and women ≥ 70 years
- Sufficient vision and hearing to complete all tests
- Proficient in spoken and written English
- Scheduled for elective, inpatient, noncardiac surgery, expected to last at least 120 minutes requiring general anesthesia
Exclusion criteria
- Urgent or emergent surgery
- Diagnosed dementia (or MoCA\<19)
- History of Parkinson's disease, major psychiatric disease (Schizophrenia), or severe traumatic brain injury
- Ongoing alcohol or substance abuse (per DSM V criteria)
- Allergy to propofol or sevoflurane
- Personal or family history of malignant hyperthermia
- Planned postoperative intubation
- Brain surgery
- Surgery requiring TIVA or GAS (i.e. cases involving neuromonitoring)
- Surgical procedure requiring general anesthetic occurring within 3 months (before or after) surgical date
- Any patient or perioperative factor considered a contraindication to randomization to either experimental group by the surgeon or anesthesiologist.
Recruiting US locations
Oregon Health & Science University
Portland, OR 97239
Site contact: Sarah Feller, BS · fellersa@ohsu.edu
Study contacts (from the official record)
- Kimberly N. Chun, BS · 503-494-7437 · chunk@ohsu.edu
- Sarah L. Feller, BS · 503-494-6233 · fellersa@ohsu.edu
Similar studies in Oregon
All healthy volunteers studies in Oregon →- RecruitingHealthy volunteersPhase 1/Phase 2
A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)
Novartis Pharmaceuticals
- Location
- Bend, OR + 18 other US sites
- Eligibility basics
- Ages 18–100
- RecruitingHealthy volunteersPhase 1/Phase 2
Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination
Oregon Health and Science University
- Location
- Portland, OR
- Eligibility basics
- Ages 20–49
- RecruitingHealthy volunteersEarly Phase 1
Monoferric for Prenatal Iron Deficiency
Oregon Health and Science University
- Location
- Portland, OR
- Eligibility basics
- Ages 18–65 · Women only
- RecruitingHealthy volunteersPhase 3
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Location
- Portland, OR + 55 other US sites
- Eligibility basics
- Ages 18–79